A detailed history of Parallel Advisors, LLC transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 11 shares of ITOS stock, worth $91. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11
Previous 53 79.25%
Holding current value
$91
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$10.09 - $17.97 $423 - $754
-42 Reduced 79.25%
11 $0
Q2 2024

Aug 08, 2024

BUY
$10.33 - $18.09 $433 - $759
42 Added 381.82%
53 $0
Q4 2023

Feb 09, 2024

BUY
$8.57 - $11.06 $94 - $121
11 New
11 $0
Q2 2023

May 20, 2024

BUY
$12.93 - $18.05 $814 - $1,137
63 Added 38.41%
227 $3,000
Q2 2023

Aug 04, 2023

BUY
$12.93 - $18.05 $814 - $1,137
63 Added 38.41%
227 $3,000
Q1 2023

May 20, 2024

BUY
$13.02 - $22.62 $1,992 - $3,460
153 Added 1390.91%
164 $2,000
Q1 2023

Apr 25, 2023

BUY
$13.02 - $22.62 $2,135 - $3,709
164 New
164 $2,000
Q2 2022

Aug 01, 2022

BUY
$16.57 - $35.1 $132 - $280
8 New
8 $0
Q2 2021

Aug 06, 2021

SELL
$17.9 - $36.1 $89 - $180
-5 Closed
0 $0
Q1 2021

Apr 23, 2021

BUY
$30.86 - $44.2 $154 - $221
5 New
5 $0

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $295M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.